AIKI Key Statistics, Chart & Performance
The current stock price of AIKI is 3.56 USD. In the past month the price decreased by -10.1%. In the past year, price decreased by -67.28%.
AIKI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.28 | 388.89B | ||
| AMGN | AMGEN INC | 14.89 | 175.30B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.11B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.53 | 116.86B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.06 | 80.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 727.27 | 49.00B | ||
| INSM | INSMED INC | N/A | 35.77B | ||
| NTRA | NATERA INC | N/A | 32.49B | ||
| BIIB | BIOGEN INC | 11.09 | 27.23B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.65B | ||
| INCY | INCYTE CORP | 16.56 | 20.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.28 | 20.77B |
Related stock screener links
About AIKI
Company Profile
AIkido Pharma, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The Company’s pipeline consists of patented technology from universities and researchers. The firm advances its therapeutic drug pipeline through a collaboration with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The company is also developing a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. Its pancreatic drug candidate, DHA-dFdC, developed at and licensed from the University of Texas at Austin, is a chemotherapy treatment for advanced pancreatic cancer.
Company Info
AIKIDO PHARMA INC
One Rockefeller Plaza, 11Th Floor
New York City NEW YORK 10020 US
CEO: Anthony Hayes
Employees: 4
Phone: 13473217646.0
AIKIDO PHARMA INC / AIKI FAQ
What does AIKI do?
AIkido Pharma, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The Company’s pipeline consists of patented technology from universities and researchers. The firm advances its therapeutic drug pipeline through a collaboration with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The company is also developing a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. Its pancreatic drug candidate, DHA-dFdC, developed at and licensed from the University of Texas at Austin, is a chemotherapy treatment for advanced pancreatic cancer.
What is the current price of AIKI stock?
The current stock price of AIKI is 3.56 USD. The price increased by 0.28% in the last trading session.
What is the dividend status of AIKIDO PHARMA INC?
AIKI does not pay a dividend.
What is the ChartMill technical and fundamental rating of AIKI stock?
AIKI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy AIKI stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AIKI.
Can you provide the market cap for AIKIDO PHARMA INC?
AIKIDO PHARMA INC (AIKI) has a market capitalization of 19.53M USD. This makes AIKI a Nano Cap stock.
AIKI Technical Analysis
AIKI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AIKI. The financial health of AIKI is average, but there are quite some concerns on its profitability.
AIKI Financial Highlights
Over the last trailing twelve months AIKI reported a non-GAAP Earnings per Share(EPS) of -3.37. The EPS decreased by -879.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
AIKI Forecast & Estimates
7 analysts have analysed AIKI and the average price target is 16.32 USD. This implies a price increase of 358.43% is expected in the next year compared to the current price of 3.56.